New partnership between GC Labs and KNCV Tuberculosis Foundation to strengthen tuberculosis treatment safety monitoring

GC Labs and KNCV Tuberculosis Foundation (KNCV) will present their newly formed alliance during an online event on the 18th of August. The two organizations will collaborate on a project for ‘Strengthening tuberculosis (TB) treatment Safety Monitoring’ in Kyrgyzstan and Vietnam. The project is aimed at quality control of non-bacteriological tests, for example, blood tests. These tests are crucial to monitor the wellbeing of patients starting on the novel and existing tuberculosis treatments. The early detection of any drug adverse effects and intolerance is essential to prevent undesirable consequences to the patient’s health and guides doctors in their decision-making. Improved quality of the safety monitoring system, which  healthcare professionals trust, leads to better treatment outcomes and patient safety through the long course of TB treatment (from six months to two years).

Eunhee Lee, President of GC Labs, will be present at the online event, as well as Dr. Mustapha Gidado, KNCV’s Executive Director, and Dr. Agnes Gebhard, KNCV’s Technical Director. With the help of the alliance between GC Labs and KNCV, the opportunity arises to improve the TB drug safety monitoring system in Kyrgyzstan and Vietnam. This approach will subsequently be discussed with global-level stakeholders for application and expansion in other countries as part of a standard TB care package.

Historically, the non-bacteriological laboratory tests – such as full blood count and a variety of blood chemistry tests for side effects monitoring in TB patients – have often lacked focus on quality control and standardization. When the quality of these tests fluctuates, the patient’s treatment safety can be compromised. As a result, the patient’s health can be negatively affected, and the TB treatment is interrupted with undesirable outcomes.

With the generous support of GC Labs, KNCV will  focus on this problem from the individual patient’s management level up to the global level. A significant investment by GC labs has been granted to KNCV, giving GC Labs a timely opportunity to step up its corporate social responsibility mandate. GC Labs has earned its competitive advantage by its expertise in the clinical diagnostics of patients. By partnering with KNCV, which has  118  years of experience in anti-tuberculosis activities, GC Labs contributes to KNCV’s goal; a world free of TB.

To commemorate the new partnership, a ceremony is scheduled to take place on August 18th. The partnering illustrates how countries like South Korea and international non-profit organizations such as KNCV can form alliances to defeat a common enemy and improve human health conditions in low and middle income settings. Mustapha Gidado, the Executive Director of KNCV, agrees, adding, “KNCV is honored to take part in this project with GC Labs. With the knowledge that GC Labs and KNCV have about TB control, we strongly believe that this project will greatly contribute towards relieving the suffering from TB worldwide.” In a commemorative speech, Dr. Lee Eun-hee, Chairman of the GC Laboratory, said “Our clinical laboratory has had a distinctive legacy in the clinical diagnostics field across Asia and serves  as the very first medical institution in Korea built specializing in diagnostic testing.

About GC Labs

GC Labs is the South Korea’s leading clinical laboratory, a specialist in infectious diseases, and serves as part of the Global Diagnostics Network. GC Labs has enabled patients to receive accurate diagnoses and the right treatment with unrivaled quality of routine and specialized clinical tests. Around 800 employees at GC Labs offer more than 5,000 tests and test combinations, ranging from routine tests to highly esoteric molecular and genetic assays. With more than 35 years of accumulated know-how, GC Labs values the principles of providing the best treatment for patients even in unpredictable medical environments through passionate and ceaseless efforts. Not only domestically, but GC Labs has managed to expand overseas by entering a Lab Service Agreement with different areas of the world such as Sri Lanka, Vietnam, Myanmar, Indonesia, India, UAE and etc. GC Labs is qualified with excellent medical standard of medical manpower, level, infrastructure, and etc. For further information, please visit our official website www.gclabs.co.kr/eng.

About KNCV Tuberculosis Foundation (KNCV)

KNCV has been fighting TB since its establishment in 1903. Over these 118 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in significant contributions to global evidence generation, policy development and TB program implementation worldwide. KNCV is active in the area of diagnostics by implementing a novel diagnostic tools and approaches for TB, COVID-19, other infectious diseases and Anti-Microbial Resistance.

KNCV has been fighting TB since its establishment in 1903. Over the past 117 years, the organization has acquired indispensable knowledge and experience in the field of effective TB control, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework
Our patroness
Partner with us

Tuberculosis is still one of the major causes of preventable death in the world and claims over 4000 lives a day, leading to over 1,5 million deaths a year.

Patient stories

The story of Abdurahim
The story of Fikeraddis
The story of Issayas
The story of Zarina
The story of Maxine
The story of Saanvi

Sorry

De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.